Abstract
Therapeutic induction of apoptosis is an important goal of anti-cancer drug design. Here, we review briefly the emerging role of cellular carbonyl stress in melanoma proliferative control, antiapoptotic survival signaling, progression, and metastasis. Cellular carbonyl stress mediated by endogenous reactive carbonyl species (RCS) such as glyoxal, methylglyoxal (MG), and malondialdehyde has been implicated in proliferative signaling and metastasis of human tumor cells. RCS-derived protein-epitopes called advanced glycation endproducts (AGEs) formed from chemical reaction between RCS and tissue proteins are abundant in melanoma tissue, and AGEs are potent ligands of RAGE, a membrane receptor involved in melanoma proliferation and metastasis. In addition to the established role of AGE-RAGE signaling in many human malignancies, increasing experimental evidence supports the hypothesis that RCS, originating from increased tumor cell glycolysis and mitochondrial oxidative stress, are small molecular anti-apoptotic effectors targeting the mitochondrial permeability transition pore (MPTP). We also discuss the emerging role of RCS as novel molecular targets for chemotherapeutic intervention, and provide preliminary experimental evidence that carbonyl scavengers, specific molecular antagonists of RCS, may represent a novel class of anti-melanoma therapeutics.
Keywords: apoptosis, carbonyl scavenger, carbonyl stress, melanoma, mitochondrial permeability transition pore, receptor for advanced glycation endproducts
Current Cancer Therapy Reviews
Title: An Emerging Molecular Target in Melanoma: Cellular Carbonyl Stress and the Inhibition of Mitochondrial Survival Pathways by Carbonyl Scavenger Agents
Volume: 1 Issue: 3
Author(s): Georg T. Wondrak, Myron K. Jacobson and Elaine L. Jacobson
Affiliation:
Keywords: apoptosis, carbonyl scavenger, carbonyl stress, melanoma, mitochondrial permeability transition pore, receptor for advanced glycation endproducts
Abstract: Therapeutic induction of apoptosis is an important goal of anti-cancer drug design. Here, we review briefly the emerging role of cellular carbonyl stress in melanoma proliferative control, antiapoptotic survival signaling, progression, and metastasis. Cellular carbonyl stress mediated by endogenous reactive carbonyl species (RCS) such as glyoxal, methylglyoxal (MG), and malondialdehyde has been implicated in proliferative signaling and metastasis of human tumor cells. RCS-derived protein-epitopes called advanced glycation endproducts (AGEs) formed from chemical reaction between RCS and tissue proteins are abundant in melanoma tissue, and AGEs are potent ligands of RAGE, a membrane receptor involved in melanoma proliferation and metastasis. In addition to the established role of AGE-RAGE signaling in many human malignancies, increasing experimental evidence supports the hypothesis that RCS, originating from increased tumor cell glycolysis and mitochondrial oxidative stress, are small molecular anti-apoptotic effectors targeting the mitochondrial permeability transition pore (MPTP). We also discuss the emerging role of RCS as novel molecular targets for chemotherapeutic intervention, and provide preliminary experimental evidence that carbonyl scavengers, specific molecular antagonists of RCS, may represent a novel class of anti-melanoma therapeutics.
Export Options
About this article
Cite this article as:
Wondrak T. Georg, Jacobson K. Myron and Jacobson L. Elaine, An Emerging Molecular Target in Melanoma: Cellular Carbonyl Stress and the Inhibition of Mitochondrial Survival Pathways by Carbonyl Scavenger Agents, Current Cancer Therapy Reviews 2005; 1 (3) . https://dx.doi.org/10.2174/157339405774574234
DOI https://dx.doi.org/10.2174/157339405774574234 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dendrimer-drug Conjugates in Drug Delivery and Targeting
Pharmaceutical Nanotechnology The Implications of Sortilin/Vps10p Domain Receptors in Neurological and Human Diseases
CNS & Neurological Disorders - Drug Targets The Genetic Basis of New Treatment Modalities in Melanoma
Current Drug Targets Combining Bevacizumab with Radiation or Chemoradiation for Solid Tumors: A Review of the Scientific Rationale, and Clinical Trials
Current Angiogenesis (Discontinued) Nutriproteomics – Linking Proteomics Variation with Personalized Nutrition
Current Pharmacogenomics and Personalized Medicine Brain Permeable Nanoparticles
Recent Patents on CNS Drug Discovery (Discontinued) Developments in Selective Small Molecule ATP-Targeting the Serine/Threonine Kinase Akt/PKB
Mini-Reviews in Medicinal Chemistry Wnt/β-Catenin/LEF-1 Signaling in Chronic Lymphocytic Leukemia (CLL): A Target for Current and Potential Therapeutic Options
Current Cancer Drug Targets Cellular Mechanisms that Edit the Immunopeptidome
Current Proteomics Sunlight Vitamin D and Skin Cancer
Anti-Cancer Agents in Medicinal Chemistry Marine Actinomycetes-derived Natural Products
Current Topics in Medicinal Chemistry Molecular Biomarkers for Lung Adenocarcinoma: A Short Review
Current Cancer Therapy Reviews The Antioxidant Activity of Coumarins and Flavonoids
Mini-Reviews in Medicinal Chemistry Quasi-Life Self-Organizing Systems: Based on Ensembles of Succinylated Derivatives of Interferon-Gamma
Current Medicinal Chemistry Current Perspectives in Prostate Cancer Vaccines
Anti-Cancer Agents in Medicinal Chemistry <i>In Silico</i> Evaluation of the ATP7B Protein: Insights from the Role of Rare Codon Clusters and Mutations that Affect Protein Structure and Function
Current Proteomics Molecular Targets of Omega-3 Fatty Acids for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Compounds From Celastraceae Targeting Cancer Pathways and Their Potential Application in Head and Neck Squamous Cell Carcinoma: A Review
Current Genomics Editorial (Thematic Issue: “Current Trend in Oncolytic Virus Therapy Against Cancers”)
Current Cancer Therapy Reviews DTCM-Glutarimide Hinders Growth of Childhood Leukemia Cells but Fails to Improve the Efficacy of Commonly Used Chemotherapeutic Agents
Current Bioactive Compounds